Click here to view the full activity and claim free NCPD credit! https://i3health.com/course-information/managing-immune-related-adverse-events-to-ensure-optimal-cancer-immunotherapy-outcomes-the-nurses-view

At last year’s Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit, i3 Health hosted a nursing continuing professional development (NCPD) symposium entitled Managing Immune-Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes (IRAEs): The Nurse’s View, chaired by Blanca Ledezma, MSN, NP, AOCNP®, Hematology/Oncology Nurse Practitioner at UCLA Health. With numerous advances in the immunotherapy space occurring since the symposium was held, Oncology Data Advisor Editorial Board member Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, sat down to discuss some of these updates in lung cancer and her own insights on optimal management of IRAEs from the nursing perspective.

Additional Advances in Immune-Related Adverse Events Research and Trials: Beth Sandy, MSN, CRNP

In this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes.

Learn more at: https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology/

Ontada, Microsoft, and Azure AI: Collaborating to Transform Real-Word Data Processing in Oncology

Tune in to the latest podcast episode, Best Practices and Emerging Evidence in the Treatment of Atopic Dermatitis in Children and Adolescents, where experts Dr. Peter A. Lio and Dr. Linda F. Stein Gold discuss cutting-edge advancements in pediatric AD care. Learn about new therapies, including nonsteroidal topicals, JAK inhibitors, monoclonal antibodies, and emerging treatments targeting the OX40 pathway, along with practical strategies to optimize patient outcomes. This episode is a must-listen for dermatologists, pediatricians, family medicine physicians, nurse practitioners, PAs, nurses, and other healthcare providers looking to stay current on evidence-based care for children and adolescents with AD. 

Earn CME/NCPD credit while you listen!

Click here to claim credit: i3health.com/atopic-dermatitis

Best Practices and Emerging Evidence in the Treatment of Atopic Dermatitis in Children and Adolescents

Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.

In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!

Click here to claim CME/NCPD credit: https://bit.ly/49NCaQu

What’s New With HER2: Charting New Paths in NSCLC Care Module 1 Podcast: HER2 in NSCLC: Actionable Insights and Testing Recommendations

Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.

In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!

Click here to claim CME/NCPD credit: https://bit.ly/405xEJO

What’s New With HER2: Charting New Paths in NSCLC Care Module 2 Podcast

Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel’s innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. 

Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney 


Mendel AI: Enhancing Clinical Data Processing for Empowered Clinical Decision Making With Kristin Maloney, MS, BSN, RN, OCN®, and Waqas Haque, MD, MPH

The role of artificial intelligence (AI) and machine learning (ML) in precision oncology has expanded rapidly, offering promising tools for clinicians and researchers to deliver more targeted and efficient care. During the 2024 San Antonio Breast Cancer Symposium (SABCS), Fellows Forum member Dr. Jasmin Hundal conducted an interview with Ian Maurer, Chief Technology Officer at GenomOncology, to explore the applications, challenges, and future directions of AI in oncology. 

Learn more at: https://oncfellows.com/how-ai-is-revolutionizing-precision-oncology 

How AI Is Revolutionizing Precision Oncology With Ian Maurer and Jasmin Hundal, MD, MS, MPH

Implementing AI Into Healthcare Education: The Ethical and Legal Landscape

Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology-Oncology, and Professor of Pediatrics at Keck School of Medicine at the University of Southern California (USC), is currently serving as co-chair of i3 Health’s CME/NCPD activity, Practice-Changing Advances in the Management of Hemophilia. With new developments in the field occurring over recent months, Dr. Young sat down with us to share recent updates in the hemophilia treatment and management. Afterwards, stay tuned to hear the full activity and learn how to claim free CME/NCPD credit.

Click the links below for the full activity!

Online accredited CME/NCPD activity: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia

Accredited CME/NCPD podcast: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia-podcast

Additional Advances in Hemophilia Research and Clinical Trials With Guy Young, MD

Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology-Oncology, and Professor of Pediatrics at Keck School of Medicine at the University of Southern California (USC), is currently serving as co-chair of i3 Health’s CME/NCPD activity, Practice-Changing Advances in the Management of Hemophilia. With new developments in the field occurring over recent months, Dr. Young sat down with us to share recent updates in the hemophilia treatment and management. 

Click the links below for the full activity!

Online accredited CME/NCPD activity: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia

Accredited CME/NCPD podcast: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia-podcast

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Additional Advances in Immune-Related Adverse Events Research and Trials: Beth Sandy, MSN, CRNP

Oncology Data Advisor®

Related tracks